(Q35943222)

11 August 2017

1 reference

title

Combining external beam radiotherapy with prostate brachytherapy: issues and rationale (English)

1 reference

11 August 2017

Clarissa Febles

1

1 reference

11 August 2017

Richard K Valicenti

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

64

1 reference

11 August 2017

issue

5

1 reference

11 August 2017

page(s)

855-861

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

The effect of dose on local control of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

A dose-response study for I-125 prostate implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.06.053

10.1016/J.UROLOGY.2004.06.053

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference